Engineered SIRP Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Engineered SIRP Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Authors
Keywords
-
Journal
SCIENCE
Volume 341, Issue 6141, Pages 88-91
Publisher
American Association for the Advancement of Science (AAAS)
Online
2013-05-31
DOI
10.1126/science.1238856
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment
- (2013) T. Yamauchi et al. BLOOD
- Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles
- (2013) P. L. Rodriguez et al. SCIENCE
- The future of antibodies as cancer drugs
- (2012) Janice M. Reichert et al. DRUG DISCOVERY TODAY
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts
- (2012) Alexandre P.A. Theocharides et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
- (2012) B. Edris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- CD47-signal regulatory protein- (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction
- (2011) X. W. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Features and development ofCoot
- (2010) P. Emsley et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- PHENIX: a comprehensive Python-based system for macromolecular structure solution
- (2010) Paul D. Adams et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents
- (2008) R. Lapalombella et al. CLINICAL CANCER RESEARCH
- Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47
- (2008) Deborah Hatherley et al. MOLECULAR CELL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started